Compare INTS & SINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTS | SINT |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 11.1M |
| IPO Year | 2021 | 2007 |
| Metric | INTS | SINT |
|---|---|---|
| Price | $3.71 | $2.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $38.00 | $11.00 |
| AVG Volume (30 Days) | 24.7K | ★ 36.9K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.45 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,018,000.00 |
| Revenue This Year | N/A | $30.26 |
| Revenue Next Year | N/A | $413.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.19 | $1.86 |
| 52 Week High | $8.06 | $6.78 |
| Indicator | INTS | SINT |
|---|---|---|
| Relative Strength Index (RSI) | 16.69 | 37.62 |
| Support Level | $0.31 | N/A |
| Resistance Level | $8.06 | $2.46 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 8.36 | 26.68 |
Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.